We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.34, which surpassed the Zacks Consensus Estimate by 0.86%. STE beat on earnings in three of the trailing four quarters and met once, delivering an average surprise of 2.02%.
Q2 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.43 billion, suggesting an increase of 7.4% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.38, indicating a year-over-year increase of 11.2%.
Estimate Revision Trend Ahead of STE's Q2 Earnings
Estimates for earnings have remained constant at $2.38 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the previous quarter, growth across all categories was robust. We expect this trend to have continued in the fiscal second quarter as well.
The company maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fiscal second-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to have remained robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 5.9% from the year-ago reported figure.
Applied Sterilization Technologies (“AST”)
In the fiscal second quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, global MedTech customers are once again expected to have remained stable, and the company is likely to have experienced an increase in bioprocessing demand. We expect these to have contributed to STE’s top-line performance in the to-be-reported quarter.
Per our model, AST segment’s revenues for the quarter are likely to increase 10.8% year over year.
The segment's fiscal first-quarter 2025 revenues rose year over year due to strong growth in consumables and services revenues. This trend might have continued in the to-be-reported quarter. Also, the segment’s margin is expected to have benefited from a favorable mix, pricing and productivity.
Our model projects the segment’s revenues to increase 7.2% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter’s figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STERIS to Report Q2 Earnings: Here's What to Expect
Key Takeaways
STERIS plc (STE - Free Report) is scheduled to release second-quarter fiscal 2026 results on Nov. 6, after market close.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.34, which surpassed the Zacks Consensus Estimate by 0.86%. STE beat on earnings in three of the trailing four quarters and met once, delivering an average surprise of 2.02%.
Q2 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.43 billion, suggesting an increase of 7.4% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.38, indicating a year-over-year increase of 11.2%.
Estimate Revision Trend Ahead of STE's Q2 Earnings
Estimates for earnings have remained constant at $2.38 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the previous quarter, growth across all categories was robust. We expect this trend to have continued in the fiscal second quarter as well.
The company maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fiscal second-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to have remained robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 5.9% from the year-ago reported figure.
Applied Sterilization Technologies (“AST”)
In the fiscal second quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, global MedTech customers are once again expected to have remained stable, and the company is likely to have experienced an increase in bioprocessing demand. We expect these to have contributed to STE’s top-line performance in the to-be-reported quarter.
Per our model, AST segment’s revenues for the quarter are likely to increase 10.8% year over year.
Teleflex Incorporated Price and EPS Surprise
Teleflex Incorporated price-eps-surprise | Teleflex Incorporated Quote
Life Sciences
The segment's fiscal first-quarter 2025 revenues rose year over year due to strong growth in consumables and services revenues. This trend might have continued in the to-be-reported quarter. Also, the segment’s margin is expected to have benefited from a favorable mix, pricing and productivity.
Our model projects the segment’s revenues to increase 7.2% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently has a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +32.65% and a Zacks Rank #1 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 329.87%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is expected to increase 147.6% from the year-ago quarter's figure.
ANI Pharmaceuticals (ANIP - Free Report) has an Earnings ESP of +1.15% and a Zacks Rank #2 at present. The company is expected to release third-quarter 2025 results soon.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 22.66%. Per the Zacks Consensus Estimate, ANIP’s third-quarter EPS is expected to surge 29.9% from the year-ago reported figure.
IDEXX Laboratories (IDXX - Free Report) has an Earnings ESP of +0.23% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2025 results on Nov. 3.
IDXX’s earnings topped estimates in each of the trailing four quarters, the average surprise being 6.08%. Per the Zacks Consensus Estimate, the company’s third-quarter EPS is anticipated to increase 12.1% from the year-ago quarter’s figure.